How Journals and Sponsors Shape Open Access in Clinical Trial Publication

Introduction: Why Open Access is Now Non-Negotiable

Open access (OA) has moved from being an academic preference to a clinical trial mandate. Regulatory agencies, funding bodies, and public advocacy groups are demanding increased transparency and wider availability of trial data. At the center of this movement are journal publishers and study sponsors, whose open access policies shape how, when, and where clinical trial results are published and accessed.

This article dives into the policies enforced by top medical journals and sponsors, the legal and ethical mandates around data dissemination, and the strategic decisions pharma professionals must make to stay compliant with evolving expectations.

Types of Open Access Models Explained

Before exploring specific policies, it’s crucial to understand the main OA models that journals and sponsors support:

• Gold Open Access: Articles are immediately free upon publication. Often involves an Article Processing Charge (APC).
• Green Open Access: Authors self-archive a version (pre-print or post-print) in a public repository after an embargo period.
• Hybrid Access: Subscription journals offer optional open access for individual articles upon payment of APC.
• Bronze Access: Articles are free to read but lack a clear reuse license.

Most clinical trial sponsors favor Gold or Green models to ensure compliance with funder mandates and transparency guidelines.

Major Sponsor Requirements for Open Access

Pharmaceutical sponsors and public agencies have begun enforcing open access publication as a formal requirement. Below is a snapshot of leading mandates:

Open Access Mandates from Major Journals

Leading medical journals have differing OA policies that authors must navigate:

• The BMJ: Full Gold OA journal. Mandates CC-BY license for research articles.
• NEJM: Subscription-based with optional OA for selected articles (high APC).
• The Lancet: Hybrid model. OA allowed with Plan S-aligned license and payment.
• JAMA: Permits Green OA after embargo. Offers OA for funder-mandated papers.
• PLOS ONE: Gold OA journal. No subscription content. APC applies to all.

Authors publishing trial results must align journal selection with sponsor obligations and transparency goals.

Plan S and the Rise of Funder-Led Publishing Requirements

Plan S is a coalition of funders including the European Commission, Wellcome Trust, and others requiring that all research they fund be published in compliant OA journals or platforms. Requirements include:

• Immediate open access without embargo
• Use of Creative Commons Attribution License (CC BY)
• Deposition in approved repositories
• Transparency in APC pricing

For clinical trial teams working under these funders, failing to publish in a compliant venue may jeopardize future funding.

Case Example: NIH-Funded Oncology Trial

A multicenter oncology trial funded by the NIH completed in 2022. As per NIH’s Public Access Policy, the manuscript was submitted to a hybrid journal that did not offer immediate open access. The team faced the following challenges:

• Delayed deposit of the accepted manuscript in PubMed Central
• Need to revise the publishing agreement to enable Green OA
• Inclusion of proper grant acknowledgment and NIH grant number

Ultimately, compliance was achieved after coordination with the publisher and NIH Manuscript Submission system (NIHMS).

Embargo Periods: How Long Can Access Be Delayed?

Embargoes refer to the time between article publication and when it becomes freely accessible in a public repository. Funders and journals vary:

• NIH: 12 months maximum
• Wellcome: No embargo allowed
• EC Horizon: Immediate access required
• NEJM: 6 months common unless OA option selected

Trial sponsors must integrate embargo planning into their publication strategy to avoid non-compliance.

Journals vs Repositories: Parallel Dissemination Strategy

Most funders allow dual routes of dissemination:

1. Journal Publication: Peer-reviewed, formal publication
2. Repository Submission: Depositing accepted manuscript in platforms like PubMed Central, Europe PMC, or institutional repositories

For example, a trial published in JAMA may have its accepted version archived in Europe PMC under funder guidelines. Both routes contribute to visibility and access.

Publication SOPs for Sponsors

Pharma companies and CROs must maintain internal SOPs that align with global OA mandates. These SOPs often include:

• Pre-submission compliance checks
• Preferred journal list with OA compatibility
• Coordination with medical writers and authors
• Archiving requirements in corporate repositories
• Communication with funders on embargo negotiations

Failure to follow these SOPs can result in inspection findings under GPP3 (Good Publication Practice) guidelines.

Best Practices for Trial Teams

• Check funder OA mandates before selecting a journal
• Choose journals indexed in trial registries or connected to ORCID/iCite
• Budget for APCs in grant or sponsor funding plans
• Document all communications with publishers regarding access rights
• Use institutional OA advisors to resolve legal conflicts

Planning ahead minimizes the risk of non-compliance and improves the trial’s dissemination timeline.

Conclusion: Ensuring Access to Scientific Knowledge

Open access policies are no longer optional — they are legally and ethically mandated across the global clinical trial landscape. Journals and sponsors play pivotal roles in ensuring trial outcomes are not locked behind paywalls. By understanding the varying models, planning for APCs, and aligning with sponsor and funder expectations, clinical research teams can ensure that trial results reach the widest possible audience — fostering public trust, advancing science, and meeting transparency goals.

Managing Delays in Clinical Trial Result Publication: Risks, Regulations, and Remedies

Why Timely Publication of Clinical Trial Results Is Critical

Publishing the results of clinical trials within a timely frame is both an ethical obligation and a regulatory requirement. Participants contribute their time and health, often with the hope of advancing medical science. When results are delayed—or not published at all—the scientific community suffers from knowledge gaps, patients are denied evidence-based options, and trust in research erodes.

Beyond ethics, global regulations demand timely disclosures. Under FDAAA 801 in the U.S., applicable clinical trials must report results on ClinicalTrials.gov within 12 months of primary completion. The European Union Clinical Trials Regulation (EU CTR 536/2014) requires sponsors to submit summary results to the Clinical Trials Information System (CTIS) within one year. Noncompliance can result in public notices, fines, or even rejection of future marketing applications.

Understanding the Common Causes of Publication Delays

Several reasons contribute to delayed publication or reporting of clinical trial results:

• Regulatory Misunderstanding: Sponsors or investigators may not fully understand the disclosure timelines, especially when managing multi-jurisdictional trials.
• Manuscript Preparation Delays: Drafting, reviewing, and finalizing scientific publications often takes months. Medical writing bottlenecks can add to this delay.
• Journal Submission Rejections: Manuscripts are frequently rejected before finding the right fit, leading to long review cycles.
• Sponsor Internal Review: Many sponsors require multi-level review, legal checks, or approval before submission—adding time.
• Negative or Inconclusive Results: Studies with non-significant findings are sometimes de-prioritized, leading to selective publication bias.

In some cases, delays are due to data verification issues, pending secondary endpoint analysis, or changes in authorship or affiliations.

Regulatory Frameworks Governing Result Publication Timelines

Different regulatory bodies have set strict timelines to reduce publication delays:

These frameworks emphasize the importance of timely and complete disclosure to avoid public health risks and regulatory action.

Consequences of Delayed or Non-Disclosure

The risks of not reporting results on time are significant:

• Ethical Breaches: Trial participants are owed transparency. Failure to publish undermines their contribution.
• Regulatory Sanctions: The FDA has issued “Notices of Noncompliance” with potential daily fines up to $13,000 per day.
• Journal Rejections: ICMJE journals require proof of timely registration and result reporting; delays can lead to manuscript rejection.
• Loss of Funding Eligibility: NIH and EU funding programs may penalize non-compliant sponsors or investigators.

In 2022, the EU posted public “transparency notices” against companies that failed to upload trial results in CTIS within required timelines, triggering reputational consequences.

Best Practices to Prevent Result Reporting Delays

To ensure timely and compliant publication, sponsors and investigators should adopt structured practices:

• Early Planning: Assign roles and draft result summaries before primary endpoint completion.
• Parallel Reporting: Prepare submissions for both clinical trial registries and scientific journals concurrently.
• Internal SOPs: Define internal timelines shorter than regulatory maximums, e.g., 9 months for result writing, 3 months for submission.
• Use of Reporting Tools: Tools like the NIHR results database and EudraCT result templates can streamline submissions.
• Monitor Registry Status: Designate staff to monitor trial registry compliance for each study.

Additionally, appointing a “Disclosure Coordinator” within the clinical operations or medical writing team can centralize accountability.

Addressing Peer Review and Journal-Related Delays

Journal submission often causes months of delay. Strategies to address this include:

• Target Open-Access Journals: Many publish within 30–45 days of acceptance.
• Consider Preprint Servers: Platforms like medRxiv allow authors to publish findings while waiting for peer review.
• Use Lay Summaries: While preparing manuscripts, publish lay summaries in trial registries for public access.

Some journals allow authors to share accepted manuscripts under embargo—this can reduce result visibility gaps.

Handling Delays in Multi-Country Trials

Multinational studies must address diverse regulatory timelines. EU CTR and FDAAA may overlap or diverge. Tips include:

• Maintain a disclosure tracker with all country-specific timelines
• Use harmonized templates across regions
• Engage local affiliates to ensure prompt translations and compliance

Failure to coordinate globally can result in some registries being updated while others remain out-of-date, increasing risk of enforcement actions.

Conclusion: Aligning Science, Ethics, and Compliance

Timely publication of trial results is more than a regulatory checkbox—it’s a fundamental scientific and ethical duty. By implementing internal controls, embracing technology, and understanding global requirements, sponsors and investigators can mitigate publication delays.

Delays not only weaken trust but also jeopardize funding, partnerships, and patient safety. In today’s environment of heightened transparency expectations, organizations must view timely disclosure as a core function of trial conduct—not a post-study formality.

Understanding Open Access Policies in Clinical Trial Publishing

Introduction: The Rise of Open Access in Clinical Research

Open access (OA) publishing is transforming the way clinical trial results are shared with the global scientific community and the public. Traditionally, medical journals operated on subscription-based models, limiting the visibility of research. Today, funders, regulators, and journals are driving an unprecedented shift toward open access—making clinical trial data more accessible, transparent, and reusable.

Open access is not just about free reading. It involves rights for reuse, public archiving, and in many cases, funder compliance. In this article, we’ll explore the major open access models, policies of leading medical journals, and implications for trial sponsors and investigators aiming for transparent publication of their clinical data.

Types of Open Access: Gold, Green, and Hybrid

There are three core models of open access relevant to trial publications:

• Gold OA: Articles are made immediately available by the publisher under an open license (e.g., Creative Commons). Authors or sponsors usually pay an Article Processing Charge (APC).
• Green OA: Authors self-archive a preprint or postprint version in an institutional or subject repository (e.g., Europe PMC), typically after an embargo period.
• Hybrid OA: Subscription-based journals offer individual OA options for an APC while keeping other content behind paywalls.

Understanding these models helps researchers select suitable journals that align with sponsor or regulatory OA requirements, such as the European Union’s Horizon 2020/Europe mandate or NIH’s Public Access Policy.

OA Policies of Leading Medical Journals

Each major medical journal or publisher has its own open access policy. Here is a comparative overview of key players:

Before submission, authors should review individual journal policies, which are often detailed under “Instructions for Authors” or “Open Access” sections.

Funder and Institutional OA Requirements

Funding agencies increasingly mandate open access to published trial results. Notable examples include:

• NIH (USA): Requires deposition in PubMed Central within 12 months.
• Horizon Europe: Immediate gold OA with CC BY licensing required.
• Wellcome Trust: Supports full gold OA with APC coverage.
• Bill & Melinda Gates Foundation: Mandates immediate OA via PubMed Central or equivalent.
• WHO: Strongly encourages OA publication for all WHO-funded trials.

Non-compliance can affect future funding eligibility or trigger audits. Clinical teams should plan publication strategies in alignment with funder policies during trial planning stages.

Plan S and Its Impact on Trial Publishing

Plan S is an international OA initiative requiring all scholarly publications funded by cOAlition S members to be published in compliant open access journals or platforms. It affects trial sponsors in the EU, UKRI (UK), and some global health agencies.

Plan S compliance requires:

• Immediate availability (no embargo)
• Publishing under a CC BY license
• Disclosure of all fees (transparency in APCs)

Many major journals now offer Plan S-compliant routes, but authors must verify compliance before submission.

Managing APCs and Sponsor Budgeting

Article Processing Charges (APCs) can be significant—ranging from $1,500 to over $10,000 depending on the journal. Trial sponsors should:

• Include APCs in trial budgets from the outset
• Negotiate institutional discounts or use transformative agreements
• Prioritize journals with tiered pricing for LMIC authors if applicable

Some publishers (e.g., Springer Nature, Elsevier) have national-level deals that waive or reduce APCs for researchers in certain countries or institutions.

Transparency Beyond Access: Data and Protocols

Modern OA policies increasingly extend beyond the article to include:

• Trial Protocols: Published as supplementary material or in protocol journals (e.g., BMJ Open)
• Datasets: Linked to repositories like Dryad, Figshare, or institutional databases
• Analysis Code: Shared via GitHub or repositories with DOIs

This reinforces reproducibility and is encouraged under ICMJE and SPIRIT guidelines. Some journals require a Data Availability Statement or Data Sharing Statement per ICMJE.

Choosing the Right Journal: Key Considerations

Before submission, evaluate journals using the following criteria:

• OA policy and licensing terms
• Indexing in PubMed, DOAJ, Scopus, etc.
• Impact Factor and readership relevance
• Funder compliance (Plan S, NIH, Gates)
• Costs and APC waivers

Resources like the Journal Checker Tool help match journals with funder mandates and OA routes.

Conclusion: Open Access is Now a Regulatory and Ethical Norm

The shift to open access in clinical trial publishing is not just a publishing trend—it’s a compliance imperative. Sponsors and investigators must now navigate funder rules, licensing standards, APC costs, and journal requirements to ensure that trial results reach the public without barriers.

By planning early, selecting journals strategically, and aligning with global transparency norms, research teams can meet ethical obligations, enhance visibility, and ensure continued eligibility for funding and regulatory goodwill.